Analyst Price Targets — CADL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 29, 2026 10:52 am | Andres Maldonado | H.C. Wainwright | $23.00 | $9.68 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Candel Therapeutics Inc. (CADL) |
| July 13, 2026 9:35 am | Stephen Willey | Stifel Nicolaus | $22.00 | $9.49 | TheFly | Candel Therapeutics initiated with a Buy at Stifel |
| October 27, 2025 8:34 pm | — | Stephens | $15.00 | $5.40 | TheFly | Candel Therapeutics initiated with an Overweight at Stephens |
Latest News for CADL
NEEDHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on August 31, 2026, the Compensation Committee of Candel's Board of Directors (the Board) granted to two new employees, stock options…
NEEDHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that Paul Peter Tak, M.D.
Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.
NEEDHAM, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.
Candel Therapeutics NASDAQ: CADL is advancing two off-the-shelf viral immunotherapy candidates designed for local administration intended to generate systemic immune responses against tumors, Chief Scientific Officer Francesca Barone said at the Canaccord Genuity Growth Conference in Boston.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CADL.
U.S. House Trading
No House trades found for CADL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.